Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 18, 2025
Product Development

2025 catalysts: New modality showdowns 

Genetic therapies compete in the same indications, as degraders come of age
BioCentury | Oct 31, 2024
Deals

Trend watch: Degrader deals show glues are sticking

At least seven molecular glue degrader deals announced this year; less deal activity for classical PROTACs
BioCentury | Oct 29, 2024
Deals

Novartis adds another degrader, this time from Monte Rosa

Deals report: AbbVie acquires Aliada, Roche returns tau mAb to UCB, Monopar licenses AZ’s Wilson disease program, and more
BioCentury | Oct 16, 2024
Discovery & Translation

Science Spotlight: Better genomic predictors for Black AML patients 

BioCentury’s roundup of translational innovations also includes a method for continuous base edits, plus updates from Monte Rosa and ImCheck
BioCentury | Aug 1, 2024
Distillery Therapeutics

PIK3CG-degrading PROTAC for AML

BioCentury | Jun 6, 2024
Discovery & Translation

Science Spotlight: Engineered CD47 protects CAR T cells from macrophages and more

BioCentury’s roundup of translational innovations
BioCentury | May 31, 2024
Distillery Therapeutics

NUDT1 PROTAC for MYC-driven cancers

BioCentury | May 23, 2024
Product Development

Amphista degrades a cancer target using a non-traditional ligase

Amphista’s targeted glues combine the advantages of PROTACs and molecular glues to create selective, orally bioavailable therapies
BioCentury | Mar 30, 2024
Discovery & Translation

Combining ADCs with protein degraders could widen the therapeutic windows of both

Degrader-antibody conjugates double up on selectivity, but ‘DACs’ present optimization challenge
BioCentury | Mar 23, 2024
Discovery & Translation

Science spotlight: AbbVie’s ADC for inflammation, plus HepaRegeniX’s liver failure therapy and more

BioCentury’s roundup of translational innovations
Items per page:
1 - 10 of 65